A Form 4 filed with the SEC on August 12, 2026, discloses that Albert Bourla, Chairman and CEO of Pfizer Inc, purchased 38,000 shares of Pfizer common stock on August 12, 2026.

Key Highlights

  • Reporting person: Albert Bourla, serving as Chairman and CEO of Pfizer Inc (NYSE:PFE)
  • Transaction: Purchase (Code P) of 38,000 shares of Pfizer common stock on 08/12/2026
  • Price paid: $26.34 per share
  • Direct ownership following transaction: 429,173 shares held directly
  • Indirect ownership: 6,382 shares held indirectly by Rule 16b-3 Plan
  • Filing signed: By Shanice A. Reid, by power of attorney, for Albert Bourla, dated 08/12/2026

Bourla's August 2026 Open-Market Purchase of Pfizer Common Stock

According to the Form 4 filed with the SEC, Albert Bourla, who is identified in the filing as both a Director and Officer holding the title of Chairman and CEO, acquired 38,000 shares of Pfizer Inc common stock on August 12, 2026. The transaction is recorded with code "P," indicating an open-market purchase, at a price of $26.34 per share. The filing covers transactions at Pfizer Inc, listed under the ticker PFE.

Following the reported purchase, the filing discloses that Bourla directly holds 429,173 shares of Pfizer common stock. In addition, the filing reports 6,382 shares held indirectly through a Rule 16b-3 Plan. No derivative securities transactions are reported in Table II of the filing.

The Form 4 was filed on August 12, 2026, the same date as the earliest transaction reported. The signature block indicates the form was signed by Shanice A. Reid, acting by power of attorney for Albert Bourla, on 08/12/2026. No amendment date is listed, indicating this is an original filing and not a revision to a prior submission.

What Was Disclosed

The filing reports a single open-market purchase of 38,000 shares of Pfizer common stock by Chairman and CEO Albert Bourla at $26.34 per share on August 12, 2026, resulting in direct beneficial ownership of 429,173 shares and indirect ownership of 6,382 shares.